Jillian E. Thompson, NP

Expert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.

Moving on to discuss the second patient case of ALK+ NSCLC, expert panelists elucidate the sequencing ALK TKIs following progression on first-line therapy.

Following their review of clinical trial data behind frontline ALK TKIs in NSCLC, key opinion leaders share practical insight on selection and use of these agents.

Focusing on the CROWN clinical trial in ALK+ NSCLC, expert panelists consider the role of frontline lorlatinib therapy in this setting.

Shared perspectives on the frontline use of brigatinib therapy in ALK+ NSCLC and results from the ALTA-1L clinical trial.

Centering discussion on clinical trial data in ALK+ NSCLC, panelists highlight the frontline use of alectinib in the ALEX study.

A panel of experts considers which factors best inform selection of first-line ALK TKI therapy in patients with non–small cell lung cancer.

Comprehensive discussion on molecular testing strategies utilized in non–small cell lung cancer to help inform treatment decisions.

Shared insight on a patient case of ALK+ non–small cell lung cancer with CNS metastasis and the role of brain MRIs in clinical practice.

Expert panelists open their discussion on ALK+ non–small cell lung cancer and reflect on the impact of CNS metastasis in this setting.